+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Atopic Dermatitis Drugs Market Research Report by Route of Administration (Injectable ROA, Oral ROA, and Tropical ROA), Drug Class, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5122188
  • Report
  • April 2022
  • Region: United States
  • 111 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • AbbVie Inc.
  • Biofrontera AG
  • Eli Lilly and Company
  • Fujisawa Healthcare
  • GlaxoSmithKline PLC
  • LEO Pharma A/S
The United States Atopic Dermatitis Drugs Market size was estimated at USD 1,436.37 million in 2021, USD 1,609.39 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.55% to reach USD 2,349.95 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Atopic Dermatitis Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Route of Administration, the market was studied across Injectable ROA, Oral ROA, and Tropical ROA.
  • Based on Drug Class, the market was studied across Biologics, Calcineurin Inhibitors, Corticosteroids, and PDE4 Inhibitors.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Atopic Dermatitis Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Atopic Dermatitis Drugs Market, including AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol-Myers Squibb Company, Connectics Corporation, Eli Lilly and Company, Encore Dermatology, Inc, Fujisawa Healthcare, Galderma S.A., GlaxoSmithKline PLC, Hoffmann-La Roche AG, LEO Pharma A/S, Meda AB, Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Atopic Dermatitis Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Atopic Dermatitis Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Atopic Dermatitis Drugs Market?
4. What is the competitive strategic window for opportunities in the United States Atopic Dermatitis Drugs Market?
5. What are the technology trends and regulatory frameworks in the United States Atopic Dermatitis Drugs Market?
6. What is the market share of the leading vendors in the United States Atopic Dermatitis Drugs Market?
7. What modes and strategic moves are considered suitable for entering the United States Atopic Dermatitis Drugs Market?
Frequently Asked Questions about the U.S. Atopic Dermatitis Drugs Market

What is the estimated value of the U.S. Atopic Dermatitis Drugs Market?

The U.S. Atopic Dermatitis Drugs Market was estimated to be valued at $1436.4 Million in 2021.

What is the growth rate of the U.S. Atopic Dermatitis Drugs Market?

The growth rate of the U.S. Atopic Dermatitis Drugs Market is 8.5%, with an estimated value of $2350.0 Million by 2027.

What is the forecasted size of the U.S. Atopic Dermatitis Drugs Market?

The U.S. Atopic Dermatitis Drugs Market is estimated to be worth $2350.0 Million by 2027.

Who are the key companies in the U.S. Atopic Dermatitis Drugs Market?

Key companies in the U.S. Atopic Dermatitis Drugs Market include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol, Myers Squibb Company, Connectics Corporation, Eli Lilly and Company and Fujisawa Healthcare.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Biofrontera AG
  • Eli Lilly and Company
  • Fujisawa Healthcare
  • GlaxoSmithKline PLC
  • LEO Pharma A/S

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Atopic Dermatitis Drugs Market, by Route of Administration
6.1. Introduction
6.2. Injectable ROA
6.3. Oral ROA
6.4. Tropical ROA
7. Atopic Dermatitis Drugs Market, by Drug Class
7.1. Introduction
7.2. Biologics
7.3. Calcineurin Inhibitors
7.4. Corticosteroids
7.5. PDE4 Inhibitors
8. California Atopic Dermatitis Drugs Market9. Florida Atopic Dermatitis Drugs Market10. Illinois Atopic Dermatitis Drugs Market11. New York Atopic Dermatitis Drugs Market12. Ohio Atopic Dermatitis Drugs Market13. Pennsylvania Atopic Dermatitis Drugs Market14. Texas Atopic Dermatitis Drugs Market
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. AbbVie Inc.
16.2. Bausch Health Companies Inc.
16.3. Bayer AG
16.4. Biofrontera AG
16.5. Bristol-Myers Squibb Company
16.6. Connectics Corporation
16.7. Eli Lilly and Company
16.8. Encore Dermatology, Inc
16.9. Fujisawa Healthcare
16.10. Galderma S.A.
16.11. GlaxoSmithKline PLC
16.12. Hoffmann-La Roche AG
16.13. LEO Pharma A/S
16.14. Meda AB
16.15. Mylan N.V.
16.16. Novartis AG
16.17. Pfizer Inc.
16.18. Regeneron Pharmaceuticals, Inc
16.19. Sanofi S.A.
16.20. Teva Pharmaceutical Industries Ltd
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: DYNAMICS
FIGURE 2. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (%)
FIGURE 3. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2027
FIGURE 5. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, 2019-2027 (USD MILLION)
FIGURE 6. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 7. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, 2019-2027 (USD MILLION)
FIGURE 8. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 9. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, 2019-2027 (USD MILLION)
FIGURE 10. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 11. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 12. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 14. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, 2019-2027 (USD MILLION)
FIGURE 15. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 16. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 17. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 18. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2019-2027 (USD MILLION)
FIGURE 19. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 20. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 21. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 22. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 23. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 24. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES ATOPIC DERMATITIS DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY STATE, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY STATE, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: SCORES
TABLE 13. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: BUSINESS STRATEGY
TABLE 14. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: PRODUCT SATISFACTION
TABLE 15. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: RANKING
TABLE 16. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 17. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: MERGER & ACQUISITION
TABLE 18. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 19. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 20. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: INVESTMENT & FUNDING
TABLE 21. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 22. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Connectics Corporation
  • Eli Lilly and Company
  • Encore Dermatology, Inc
  • Fujisawa Healthcare
  • Galderma S.A.
  • GlaxoSmithKline PLC
  • Hoffmann-La Roche AG
  • LEO Pharma A/S
  • Meda AB
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown

Loading
LOADING...